Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate 12:45:31 2026-10-08 EDT 5-day change 1st Jan Change
16.90 USD -5.82% Intraday chart for Summit Therapeutics Inc. +1.86% -2.80%

Valuation: Summit Therapeutics Inc.

Market Cap 10.87B 14.36B 12.83B 11.97B 20.45B 1,391B 20.65B 144B 56.19B 707B 53.93B 52.76B 2,273B P/E 2026 *
-15.6x
P/E 2027 * -15.5x
Enterprise Value 10.4B 13.74B 12.27B 11.45B 19.57B 1,331B 19.76B 137B 53.76B 676B 51.6B 50.48B 2,175B EV / Sales 2026 *
3,543x
EV / Sales 2027 * 255x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
09-22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
09-15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
09-14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
08-26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
08-26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
08-26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
08-25 Wall Street Wants Receipts Zonebourse
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day-5.65%
1 week+1.86%
Current month+0.53%
1 month-1.62%
3 months+8.35%
6 months-9.62%
Current year-2.80%
1 week 16.44
Extreme 16.44
18.33
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 2022-07-24
Chief Executive Officer 81 2020-03-31
Director of Finance/CFO 48 2024-04-01
Director TitleAgeSince
Chairman 81 2020-01-31
Director/Board Member 48 2019-11-30
Director/Board Member 55 2020-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-5.82%+1.86%-27.16%+917.96% 14.36B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-8.35%-10.98%+283.29%+619.63% 43.05B
-1.86%-2.85%+26.27%+26.94% 42.48B
-5.66%-4.14%-2.04%+99.04% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.14%-4.65%-13.11%-15.52% 23.93B
-3.57%-9.85%-39.50%+299.41% 22.22B
Average -5.18%-1.75%+28.60%+216.82% 40.05B
Weighted average by Cap. -5.64%-1.59%+38.79%+159.91%

Financials

2026 *2027 *
Net sales 2.94M 3.88M 3.46M 3.23M 5.52M 376M 5.58M 38.79M 15.17M 191M 14.56M 14.25M 614M 41.88M 55.34M 49.42M 46.11M 78.81M 5.36B 79.58M 554M 217M 2.72B 208M 203M 8.76B
Net income -701M -926M -827M -771M -1.32B -89.66B -1.33B -9.26B -3.62B -45.56B -3.48B -3.4B -147B -743M -982M -877M -818M -1.4B -95.09B -1.41B -9.82B -3.84B -48.32B -3.69B -3.61B -155B
Net Debt -470M -621M -555M -517M -884M -60.14B -893M -6.21B -2.43B -30.56B -2.33B -2.28B -98.29B -200M -264M -236M -220M -377M -25.61B -380M -2.65B -1.03B -13.01B -993M -971M -41.86B
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
26-10-08 US$16.96 -5.54% 3,128,412
26-10-07 US$17.95 +3.70% 8,175,297
26-10-06 US$17.31 +0.23% 5,875,829
26-10-05 US$17.27 +3.07% 5,277,704
26-10-02 US$16.76 +0.39% 5,196,190
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.59GBP
Average target price
22.51GBP
Spread / Average Target
+65.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock